Ejaculating Every Day Keeps the Doctor Away?

Ejaculating Every Day Keeps the Doctor Away?

fivetimesaweekThis image, spreading over the Internet, suggests that frequent ejaculation lowers the risk of prostate cancer by a third. But is it also true? We checked the original research paper to find out.

The researchers studied men under 70 with (n=1079) and without (n=1259) prostate cancer. The subjects were asked to report the average number of times that they had ejaculated per week in their most sexually active year in each of three decades of age: their 20’s, 30s and 40s.

The researchers found a significant negative relationship between risk on prostate cancer and number of ejaculations for men in their 20s (and not in their 30s and 40s). The results suggest that men who have on average five or more ejaculations per week in their 20s have a lower risk on developing prostate cancer than those who ejaculate less often in their 20s.

“Ejaculatory frequency, especially in early adult life, is negatively associated with the risk of prostate cancer, and thus the molecular biological consequences of suppressed or diminished ejaculation are worthy of further research,” the researchers conclude.

So gentleman, when you’re still in your 20s it seems beneficial to ejaculate at least 5 times a week. But if it reduces the risk of prostate cancer by a third is not confirmed by this research.


Giles, G., Severi, G., English, D., McCredie, M., Borland, R., Boyle, P., & Hopper, J. (2003). Sexual factors and prostate cancer BJU International, 92 (3), 211-216 DOI: 10.1046/j.1464-410X.2003.04319.x

ejaculation health, kanker mannen

Carian Thus

We believe that science should be available to everyone, everywhere. Delivering well-supported stories, written by experts, about scientific discoveries requires hard work. We strive to meet our audience's standards. Your contribution will keep our magazine running free of charge.

Support United Academics
Support Open Access to Science

Creative Commons Licence
United Academics Magazine is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.